Author: Ryan Allway

VANCOUVER, April 1, 2019 /PRNewswire/ – Village Farms International, Inc. (“Village Farms” or the “Company”)  (TSX: VFF) (NASDAQ: VFF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has exercised its option on the existing 1.1 million square foot Delta 2 greenhouse facility currently owned by Village Farms in Delta, British Columbia.  The Delta 2 facility is a newer, nearly identical “sister” facility immediately adjacent to the 1.1 million square foot Delta 3 greenhouse facility, which is already one of the largest cannabis production operations in the world.

The addition of the Delta 2 greenhouse operation doubles Pure Sunfarms’ total production area to 2.2 million square feet and, with conservatively targeted annual production of approximately 75,000 kilograms of dried cannabis, doubles its annual cannabis production potential to approximately 150,000 kilograms.  Pure Sunfarms also expects to benefit from further economies of scale resulting from the concentration of 2.2 million square feet of production area at a single location, which will further support the Company’s goal to be the high-quality, low-cost cannabis producer in Canada.  The existing automated propagation operation (nursery) in the Delta 3 facility will provide propagation for the Delta 2 facility, enabling more of the footprint of the Delta 2 facility to be devoted to flower rooms than in Delta 3, which is expected to generate further cost efficiencies.

“With an ongoing shortage of supply from Canadian cannabis producers, Village Farms is thrilled that Pure Sunfarms’ has made the decision to more than double its production capacity with the addition of Delta 2 – just three weeks after the option became exercisable,” said Michael DeGiglio, Chief Executive Officer, Village Farms and Co-Chair, Pure Sunfarms.

“Pure Sunfarms is setting itself apart amongst the top echelon of Canadian licensed producers, achieving its conversion and production ramp up milestones, meeting or exceeding expectations on quality, yield and cost, and delivering profitability in its first full quarter of operations.  The unmitigated success of the conversion, licensing and production ramp up of the Delta 3 facility, alongside the outstanding performance of Pure Sunfarms’ management and operational teams, gives us great confidence in their ability to execute on the Delta 2 facility.  Delta 2 will also benefit from the continued support of Village Farms, with its decades of large-scale, low-cost operational experience and greenhouse design and systems acumen, as well as the significant learnings gained through the conversion and ramp up of the Delta 3 facility.”

Mr. DeGiglio added, “Exceptional growing operations are the foundation of great agricultural brands. Pure Sunfarms is already one of the largest and most capable producers in the Canadian cannabis industry and more than doubling its production capacity will further leverage this crucial competitive advantage as it establishes itself as a premier vertically integrated supplier.  I look forward to reporting on the continued progress at Pure Sunfarms, and the significant contribution of that progress to Village Farms’ financial results and value for our shareholders.”

Pure Sunfarms will immediately begin design and procurement for the conversion of the Delta 2 facility for cannabis production. As with the Delta 3 facility, Pure Sunfarms plans a phased conversion to expedite time to production and revenue generation.  Conversion of the external infrastructure, including that for the electrical distribution system, is expected to commence in Summer 2019.  Village Farms, on behalf of Pure Sunfarms, has already secured 24 MW of power from the local utility to support supplemental lighting and post-harvest equipment at the Delta 2 facility.  As with the Delta 3 facility, personnel from the existing Village Farms growing and maintenance teams and skilled labour force will be transitioned to Pure Sunfarms.  Pure Sunfarms is targeting to complete its first harvest at the Delta 2 facility by mid-2020 and achieve full run-rate production in the fourth quarter of 2020.  All targeted production timelines are subject to the timing and receipt of requisite Health Canada licenses.  Pure Sunfarms plans to begin the process of applying for a cultivation license for the Delta 2 facility as soon as possible, which it will pursue as a “second-site” license application.

In accordance with the terms of the joint venture agreement with Emerald Health Therapeutics (“Emerald”) for Pure Sunfarms, Village Farms’ is contributing the Delta 2 facility to the joint venture and Emerald will contribute an aggregate of CAD$25 million in cash.  Emerald’s cash contribution will fund a portion of the conversion of the Delta 2 facility to cannabis production, which is estimated to cost approximately CAD$60 million, consistent with the cost of conversion of the Delta 3 facility. The remainder of the conversion costs will be funded entirely by Pure Sunfarms.

Pure Sunfarms continues to have an option on the 2.6 million square foot Delta 1 greenhouse facility, one of the single largest greenhouse footprints in North America, which is immediately adjacent to the Delta 2 and Delta 3 facilities, and which continues to be owned and operated by Village Farms.  The Delta 1 option expires on September 28, 2021.  Should Pure Sunfarms fail to exercise the Delta 1 option, the terms if the joint venture agreement permit Village Farms to convert and operate the Delta 1 facility for the production of any agricultural crop.

Mr. DeGiglio commented, “As Pure Sunfarms progresses with the conversion of the Delta 2 facility, it will evaluate the opportunity around the Delta 1 option. If the Delta 1 option is exercised, Pure Sunfarms would have a total of 4.8 million square feet of production area, which is conservatively estimated to yield a total of 330,000 kilograms of cannabis production annually, providing the potential to address a considerable portion of the entire Canadian market, while providing even greater cost efficiencies.”

Village Farms also announced that Pure Sunfarms has entered into a subsequent supply agreement with Emerald, which will commence upon the expiry of the current supply agreement at the end of 2019.  Under the new supply agreement, Emerald will purchase up to 25% of Pure Sunfarms’ production in 2020, 2021 and 2022 at prevailing wholesale market prices.

About Village Farms International, Inc.

Village Farms is one of the largest and longest-operating vertically integrated greenhouse growers in North America and the only publicly traded greenhouse produce company in Canada. Village Farms produces and distributes fresh, premium-quality produce with consistency 365 days a year to national grocers in the U.S. and Canada from more than nine million square feet of Controlled Environment Agriculture (CEA) greenhouses in British Columbia and Texas, as well as from its partner greenhouses in British Columbia, Ontario and Mexico.  The Company is now leveraging its 30 years of experience as a vertically integrated grower for the rapidly emerging global cannabis opportunity through its 50% ownership of British Columbia-based Pure Sunfarms Corp., one of the single largest cannabis growing operations in the world.  The Company also intends to pursue opportunities to become a vertically integrated leader in the U.S. hemp-derived CBD market, subject to compliance with all applicable U.S. federal and state laws.  Village Farms has established a joint venture, Village Fields Hemp, for multi-state outdoor hemp cultivation and CBD extraction and plans to pursue controlled environment hemp production at its Texas greenhouse operations, which total 5.7 million square feet of production area, subject to legalization of hemp in Texas.

Cautionary Language

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements may relate to the Company’s future outlook or financial position and anticipated events or results and may include statements regarding the financial position, business strategy, budgets, litigation, projected production, projected costs, capital expenditures, financial results, taxes, plans and objectives of or involving the Company. Particularly, statements regarding future results, performance, achievements, prospects or opportunities for the Company, Pure Sunfarms, the greenhouse vegetable industry or the cannabis and hemp industries are forward-looking statements. In some cases, forward-looking information can be identified by such terms as “outlook”, “may”, “might”, “will”, “could”, “should”, “would”, “occur”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “predict”, “potential”, “continue”, “likely”, “schedule”, “objectives”, or the negative or grammatical variation thereof or other similar expressions concerning matters that are not historical facts.

Although the forward-looking statements contained in this press release are based upon assumptions that management believes are reasonable based on information currently available to management, there can be no assurance that actual results will be consistent with these forward-looking statements. Forward-looking statements necessarily involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, that may cause the Company’s or the industry’s actual results, performance, achievements, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, the factors contained in the Company’s filings with U.S. and Canadian securities regulators, including as detailed in the Company’s annual information form and management’s discussion and analysis for the year-ended December 31, 2018.

When relying on forward-looking statements to make decisions, the Company cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties and should not be read as guarantees of future results, performance, achievements, prospects and opportunities. The forward-looking statements made in this press release only relate to events or information as of the date on which the statements are made in this press release. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Village Farms International, Inc.

GATINEAU, Quebec, April 01, 2019 (GLOBE NEWSWIRE) — HEXO Corp (TSX:HEXO; NYSE-A:HEXO) (“HEXO” or the “Company”) has completed the first harvest in its 1 million sq. ft. expansion, marking an important execution milestone in the Company’s continuous growth.

Since early January, plants have been moving into the greenhouse and the first plants have now been harvested. The Company continues to ramp up to full harvest capacity using the continuous harvest methodology, the latest step towards reaching the full annual production capacity of 108,000 kg of dried flower per year.

“Completing the first harvest in our 1,000,000 sq. ft. greenhouse expansion showcases the dedication and hard work of the entire HEXO team,” said Sébastien St-Louis, HEXO’s CEO and co-founder. “We are very proud of our continued ability to execute on our plans, creating value for our shareholders and demonstrating our commitment to our customers. This cultivation milestone means that an expanded HEXO product offering will be available to more Canadians shortly.”

HEXO Corp’s headcount now exceeds 600 employees. The Company expects to hire another 500 employees in the coming months; 300 additional position at its campus in Gatineau, Quebec, and 200 in its Belleville, Toronto and Montreal locations.

On March 13, 2019, HEXO announced a definitive arrangement agreement to acquire Newstrike Brands Ltd. The acquisition would allow the Company to boost its production capacity to 150,000 kg annually, diversify its domestic market penetration to 9 provinces and add infrastructure supporting the Company on its goal of becoming one of the top cannabis companies in the world.

About HEXO
HEXO Corp is an award-winning consumer packaged goods cannabis company that creates and distributes prize-winning products to serve the global cannabis market. Through its hub and spoke business strategy, HEXO Corp is partnering with Fortune 500 companies, bringing its brand value, cannabinoid isolation technology, licensed infrastructure and regulatory expertise to established companies, leveraging their distribution networks and capacity. As one of the largest licensed cannabis companies in Canada, HEXO Corp operates with 1.8 million sq. ft of facilities in Ontario and Quebec and a foothold in Greece to establish a Eurozone processing, production and distribution centre. The Company serves the Canadian adult-use and medical markets. For more information please visit hexocorp.com.

Forward-Looking Statements
This press release contains forward-looking information and forward-looking statements within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are based on certain expectations and assumptions and are subject to known and unknown risks and uncertainties and other factors that could cause actual events, results, performance and achievements to differ materially from those anticipated in these forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results. A more complete discussion of the risks and uncertainties facing the Company appears in the Company’s Annual Information Form and other continuous disclosure filings, which are available on SEDAR at www.sedar.com and EDGAR at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.

Investor Relations:
Jennifer Smith
1-866-438-8429
invest@HEXO.com
www.hexocorp.com

Media Relations:
Caroline Milliard
(819) 317-0526
media@hexo.com

Director:
Adam Miron
819-639-5498

LEAMINGTON, ON, April 1, 2019 /PRNewswire/ – Aphria Inc. (“Aphria” or the “Company“) (TSX: APHA and NYSE: APHA) through its subsidiary Aphria Deutschland GmbH (“Aphria Germany“) today launched the Company’s first CBD-based nutraceutical, the first product in its CBD-based cosmetics line for the German market. Featuring CBD derived from hemp, the CannRelief brand of products are being produced in the European Union and distributed by the Company’s subsidiary, CC Pharma, which has access to more than 13,000 pharmacies throughout Germany.

“We are excited to introduce our first brand of CBD products for the German nutraceutical and cosmetics market,” said Jakob Ripshtein, President of Aphria. “Supported by our extensive distribution network through CC Pharma, CannRelief provides a natural extension to Aphria’s growing business opportunities in the German medical cannabis market. We look forward to providing a full range of CannRelief CBD products this year.”

CannRelief CBD oils are being sold in both a 5% and 10% CBD concentration and can be found in select stores across Germany. A range of skincare and other products, including creams, serums and masks will be introduced under the CannRelief brand in a phased rollout in 2019. More information about CannRelief products can be found at cannrelief.de.

“Aphria continues to execute on its strategic growth initiatives in Germany,” continued Ripshtein. “We believe we have tremendous momentum in Germany and across our international business as we continue to strengthen our global footprint.”

We Have A Good Thing Growing

About Aphria

Aphria is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.

For more information, visit: aphria.ca

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to internal expectations, estimated margins, expectations with respect to actual production volumes, expectations for future growing capacity and costs, the completion of any capital project or expansions, and expectations with respect to future production costs. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE Aphria Inc.

Related Links

http://aphria.com/

TORONTO and DENVER, April 01, 2019 (GLOBE NEWSWIRE) — MJardin Group, Inc. (“MJardin” or “the Company”) (CSE: MJAR) (OTCQX: MJARF), a leader in cannabis production, is pleased to announce the completion of an Agreement (the “Agreement”), whereby the Nova Scotia Mi’kmaq First Nations (“Mi’kmaq”) will own a 51% stake in AtlantiCann Medical Inc. (“AMI”). As a result of the Agreement, MJardin and the Halef Group will own 39% and 10% of AMI, respectively. In connection with the partnership formed under the Agreement, MJardin, the Mi’kmaq and the Halef Group are contemplating expansion of their relationship, including retail.

Located in Halifax, Nova Scotia, AMI is a licensed joint venture cultivator with a 48,000 square foot facility with a production capacity of 6,000 kg per year (Phase 1), and an additional 20,000 square feet (Phase 2) expected by the end of 2019 which is anticipated to double AMI’s production capacity. AMI has been built to GMP standards and is presently undertaking the GMP certification process, anticipated to be complete in the second half of 2019.  AMI is also in the application process for a sales license with Health Canada which is anticipated to be granted by the end of September, 2019.

“We are very pleased with the level of commitment from the Mi’kmaq First Nations in the AMI partnership and the strategic value this brings to MJardin,” noted Adrian Montgomery, Chair of the board of MJardin Group. “AMI is an important asset as part of MJardin’s growth strategy as we continue our focus on ramping up sales and furthering our footprint and production assets across Canada.”

About MJardin Group

MJardin is a global cannabis management platform with extensive experience in cultivation, processing, distribution and retail. For over 10 years, MJardin has refined cultivation methodologies, developed state of the art facilities and implemented vertical integration for and on behalf of license owners. MJardin is based in Denver, Colorado and Toronto, Canada . For more information, please visit www.mjardin.com.

The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Information

This news release contains forward-looking information based on current expectations. Statements about, among other things, future developments and the business and operations of MJardin, future arrangements with either the Halef Group or the Mi’kmaq, trading of MJardin’s shares on the OTCQX Best Market, the receipt of any pending regulatory approvals or licenses, the growth of or global footprint and our intentions to leverage our scale for continued organic growth and to pursue strategic investments are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such factors include, but are not limited to: our ability to identify and pursue growth, financing and other strategic objectives, and the regulatory and economic environments in the jurisdictions we operate or intend to operate or investment in. Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that the proposed acquisition will occur and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. MJardin assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

CONTACT:
Ali Mahdavi
Capital Markets & Investor Relations
416-962-3300
Ali.mahdavi@MJardin.com

Frank Knuettel II
Chief Strategy Officer
720-613-4019
Frank.Knuettel@MJardin.com

LONG BEACH, CA, April 01, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, today announced that the Drug Enforcement Administration (DEA) has conducted a scientific review of the chemical structure of cannabidiol-­valine-hemisuccinate (CBDVHS) and determined that CBDVHS is not a regulated chemical nor controlled substance under the Controlled Substances Act.

“This is a welcomed finding by the DEA.  Their decision may help us expand the network of clinical testing sites, permit a greater cross-section of patients to participate in studies of this drug, as well as speed the initiation of clinical trials,” said Brian Murphy, MD, CEO and Chief Medical Officer of Emerald Bioscience, Inc. “Emerald is planning to study this analog of CBD for potential use in managing diseases affecting the eye, particularly those that compromise the functioning of the optic nerve, leading to vision loss.”

About Emerald Bioscience, Inc.

Emerald Bioscience is a biopharmaceutical company headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Emerald is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Emerald’s strategy is to clinically develop a number of proprietary biosynthetic compounds, alone or in combination with corporate partners.

Emerald Bioscience is part of the Emerald Group, which comprises multiple companies focused on developing pharmaceutical, botanical, and nutraceutical products providing wellness and medical benefits by interacting with the human body’s endocannabinoid system.

For more information, visit www.emeraldbio.life

FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements, including statements regarding our product development, business strategy, product branding, timing of clinical trials and commercialization of cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “contemplates,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Nemus may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Nemus’ most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Nemus disclaims any intent or obligation to update these forward-looking statements.

This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any securities that may be offered in the United States will be offered

TORONTO, April 01, 2019 (GLOBE NEWSWIRE) — WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that it has entered into a credit facility with Bank of Montreal (“BMO”). Under the terms of the credit facility, BMO will provide WeedMD up to $39 million of secured debt financing at a rate of interest that is expected to average in the low-to-high 5% per annum range over a three-year term.

The facility consists of a $33.1 million term loan, a $3.0 million equipment term loan and a $3.0 million revolving credit facility (collectively, the “Loans”), all of which mature in 2022. WeedMD may, at its discretion, repay the balance of the Loans without penalty at any time during the term.

Concurrently, WeedMD has exercised its option to purchase the Health Canada-licensed, 98-acre Strathroy property (“Strathroy”) from Perfect Pick Farms (“Perfect Pick”). The Strathroy purchase includes the licensed 610,000 sq. ft. state-of-the-art hybrid-greenhouse, more than 100,000 sq. ft. of ancillary structures and all other infrastructure and equipment as well the 50 acres of land upon which the Company intends to cultivate outdoor cannabis. Link to outdoor cultivation release here.

“Securing BMO’s support at this exciting juncture in WeedMD’s growth provides market validation in our ability to continue to execute our strategic plan with non-dilutive financing,” said Keith Merker, CEO of WeedMD. “In 2018, it took us just six months to retrofit, license and bring the first phase of our state-of-the-art greenhouse online. Less than three months later, we took down our first harvests with very compelling yields and quality. We’ve since continued to expand our licensed footprint and operations across the greenhouse and have recently announced our plans for outdoor cannabis cultivation onsite, which we expect to double our production potential with a low-cost scalable expansion.”

The interest rate for the Loans is a set margin over the Canadian dollar prime rate or a bankers’ acceptance of appropriate term. Based on the current Canadian dollar prime rate, the interest payable is expected to be in the low to high 5% per annum range over the term of the Loans. The credit facility is secured by the Company and its subsidiaries, including WeedMD’s production facilities in Strathroy, Ontario and Aylmer, Ontario, and contains customary financial and restrictive covenants. Additional details on the credit facility can be found in the Company’s documents which are available under the Company’s profile on SEDAR at www.sedar.com.

WeedMD has acquired a 100% interest in the Strathroy property from Perfect Pick for the balance due under its option agreement of $22.6 million, of which $17.6 million was paid in cash and $5 million was satisfied by the issuance of 2.5 million units (“Units“) in the capital of WeedMD.

Each Unit was comprised of one WeedMD common share at a price of $2.00 and one-quarter (1/4) of a warrant (for 625,000 total warrants), with each whole warrant exercisable into a WeedMD common share at an exercise price of $2.50 per share for five years.

For more information, access WeedMD’s investor presentation here and recently updated corporate video here.

About WeedMD Inc.
WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of cannabis products for both the medical and adult-use markets. The Company owns and operates two facilities: a 26,000 sq. ft. indoor facility in Aylmer, Ontario and a state-of-the-art greenhouse and outdoor facility located in Strathroy, Ontario. The Company currently has 136,000 square feet of licensed production space and is expected to have a total footprint of more than 550,000 square feet of indoor and greenhouse production in addition to more than 25 acres of outdoor cultivation space online in the first half of 2019. WeedMD has a multi-channeled distribution strategy that includes selling directly to medical patients, strategic relationships across the seniors’ market and supply agreements with Shoppers Drug Mart as well as six provincial distribution agencies.

Follow WeedMD On:

Facebook: https://www.facebook.com/weedmd/
LinkedIn: https://www.linkedin.com/company/weedmd/?originalSubdomain=fr
Twitter: https://twitter.com/WeedMD
Instagram: https://www.instagram.com/weedmd/

For further information, please contact:

WeedMD Inc.

Keith Merker, Chief Executive Officer
Tel: 519-765-2440 Ext. 222
Email: investor@weedmd.com

To learn more, visit us at www.weedmd.com

For Media Inquiries:

Marianella delaBarrera
VP, Communications & Corporate Affairs
Tel: 416-897-6644
Email: marianella@weedmd.com

Cautionary Statement on Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation which are based upon WeedMD’s current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy.

The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information in this news release include, but are not limited to, statements with respect to internal expectations, expectations with respect to actual production volumes, expectations for future growing capacity and the completion of any capital project or expansions. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally; the ability of WeedMD to implement its business strategies; competition; crop failure; and other risks.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, WeedMD does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for WeedMD to predict all such factors. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in WeedMD’s Annual Information Form dated December 13, 2017 (the “AIF”) and other disclosure documents of WeedMD filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the AIF and other disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

TORONTO, March 29, 2019 (GLOBE NEWSWIRE) — Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE; OTCQB: EEVVF) is pleased to announce that the remaining $4,000,000 principal amount of senior unsecured convertible debentures of the initial $10,000,000 principal amount of debentures issued by the Company in June 2018 has now been converted into common shares of the Company.  A total of 13,333,333 common shares in the capital of the Company have been issued to the holder of such debentures in accordance with the terms of the debentures.

“We are very thankful for the support of our convertible debenture holder. This conversion strengthens our balance sheet and provides us with the flexibility to prioritize resource allocation to operating activities as the Company makes headway on its business development efforts and Phase 2 expansion project.” stated Melinda Rombouts, CEO of Eve & Co.

About Eve & Co Incorporated

Eve & Co, through its wholly-owned subsidiary Natural MedCo Ltd., holds cultivation and processing licenses under the Cannabis Act (Canada) for the production and sale of various cannabis products, including dried cannabis, cannabis plants and cannabis oil. Natural MedCo Ltd. was Canada’s first female founded licensed producer of medicinal marijuana and received its cultivation license from Health Canada in 2016.

Eve & Co is led by a team of agricultural experts and has a licenced 220,000 sq. ft. scalable greenhouse production facility located in Middlesex County, Ontario with 32 acres of adjacent land for future expansion. Eve & Co has commenced construction of an additional 780,000 sq. ft. proposed expansion, bringing Eve & Co’s total anticipated greenhouse capacity to 1,000,000 sq. ft.

The Company’s website can be visited at www.evecannabis.ca

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the terms of the credit facilities and the Company’s related expansion and construction plans, future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict, including those described in the Company’s management’s discussion and analysis for the three and twelve months ended October 31, 2018 which is available on the Company’s SEDAR profile. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities law.

For further information, please contact:

TORONTO and RIONEGRO, COLOMBIA, March 29, 2019 /CNW/ – PharmaCielo Ltd. (“PharmaCielo” or the “Company“) (TSXV:PCLO), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that its Colombian subsidiary has received from the national cultivar registry approval for the listing of a further 10 strains, each of which has a prominent tetrahydrocannabinol (THC) profile.

The additional registration of the new strains to the national cultivar registry, including a unique 1:1 THC to CBD ratio strain, doubles the number of approved strains PharmaCielo holds in the registry, making it the largest holder of approved strains in Colombia. It also paves the way for the commercial registration, production and sale of the 20 unique strains.

“The approval and registration of a second set of strains with the national cultivar registry is another important step towards PharmaCielo’s goal of becoming a leading global supplier of premium medicinal-grade cannabis oils,” said Federico Cock-Correa, president and CEO of PharmaCielo Colombia Holdings S.A.S. “The range of the strains now available at our disposal for commercial production is an important advantage that sets the company apart in both the Colombian and global marketplaces.”

The announcement comes on the heels of another set of strains PharmaCielo recently registered with the national cultivar registry, including a special CBD strain with a unique 20:1 ratio profile. As both the World Health Organization and many countries around the world shift their stance in favour of medical use of CBD-dominant cannabis oils and derived products, the demand for this type of strain is expected to rise.

Dr. Delon Human, Global Head, Health and Innovation with PharmaCielo added, “The medical community has diverse requirements for cannabis oil extracts based on specific needs, and as both CBD and THC are increasingly recognized for their medicinal role, the 1:1 ratio strain that we developed and received approval for makes a very significant contribution to the range of natural medicinal options.”

The process of registering strains in Colombia is lengthy and extensive. Up to five months of regulated field trials are required, including rigorous data collection and analysis, prior to approval for registration for commercial cultivation. The process from beginning to completion can last several years. PharmaCielo has completed the regulatory process and received strain approval from the technical directorate of the ICA (Colombian Institute of Agriculture), representing a diverse range of chemotypes, with various ratios of CBD to THC.  Upon approval, which PharmaCielo has now received for 20 strains, the strains may be registered for commercial production and quota issuance based on demonstrated market demand.

PharmaCielo has submitted a further group of strains for review and potential approval.

About PharmaCielo

PharmaCielo Ltd. (TSXV:PCLO) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo’s principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its nursery and propagation centre located in Rionegro, Colombia.

The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia’s ideal location will play in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as, “expects”, “is expected”, “intends”, “believes”, or variations of such words and phrases or state that certain actions, events or results “may” or “will” be taken, occur or be achieved. Forward-looking statements include statements with respect to an increase in the global medicinal demand for CBD cannabis, the timing of approval or the receipt at all of approval of the additional strain applications awaiting approval, the ability of PharmaCielo to fulfill global demand for medicinal cannabis oil extracts, and the timing of the registration of the strains with the national cultivar registry. Forward-looking statements are based on assumptions, including with respect to PharmaCielo’s planned products, and the ability to execute its business plan that management believes are reasonable in the circumstances, but the actual results, performance or achievements of PharmaCielo’s business may be materially different from any future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including, but not limited to, the equity markets generally, risks associated with early stage companies, risks associated with the regulation of cannabis and cannabinoid derivatives, failure to obtain necessary TSXV approval, competition for PharmaCielo’s planned products, risks associated with operating in Colombia, and currency exchange risk. Accordingly, readers should not place undue reliance on forward-looking statements.

Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE PharmaCielo Ltd.

For further information: www.PharmaCielo.com; Media Relations: International: Gal Wilder, Cohn & Wolfe, +1.647.259.3261, gal.wilder@cohnwolfe.ca; Colombia: María Paula Peña Fdz., SPR GROUP S.A., PBX: 57-1 2877234, mariapaula.pena@sprgroup.biz; Investor Inquiries: investors@pharmacielo.com

Related Links

http://www.pharmacielo.com

KITCHENER, Ontario, March 29, 2019 (GLOBE NEWSWIRE) — James E. Wagner Cultivation Corporation (“JWC” or the “Corporation”) (TSX VENTURE: JWCA; OTCQX: JWCAF), is pleased to announce that on March 29, 2019, it received its cultivation licence (the “Licence”) from Health Canada for its second facility located at 530 Manitou Drive in Kitchener, Ontario (“JWC 2”).

“The licensing of JWC 2 marks the culmination of years of effort from our team. It is a tremendous accomplishment that will allow us to ramp up production to a nationally competitive scale, and also allow us to bring our products to the recreational markets across Canada. JWC 2 will also stand as a proof of concept for the GrowthSTORM Dual Droplet System as we will be implementing this equipment across the entire facility,” said Nathan Woodworth, President and Chief Executive Officer of James E. Wagner Cultivation.

The Licence is issued in respect of Phase 1 of JWC 2, a portion of the full-scale production facility, measuring 345,000 sq. ft. In anticipation of receiving the Licence, JWC prepared Phase 1 of JWC 2 to allow it to begin cannabis production immediately.

About James E. Wagner Cultivation Corporation

JWC’s wholly-owned subsidiary is a Licenced Producer under the Cannabis Regulations, formerly the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). JWC is a premium cannabis brand, focusing on producing clean, consistent cannabis. JWC uses an advanced and proprietary Dual Droplet aeroponic platform named GrowthSTORM. JWC was founded as a family company and is based on family values. JWC began as a collective of patients and growers under the Marihuana Medical Access Regulations (the precursor to ACMPR). Since its inception, JWC has remained focused on providing the best possible patient experience. JWC’s operations are based in Kitchener, Ontario. Learn more at www.jwc.ca.

For additional information about JWC, please refer to JWC’s profile on SEDAR (www.sedar.com) or the Corporation’s website: www.jwc.ca 

Notice regarding forward-looking statements:

This press release contains statements including forward-looking information for purposes of applicable securities laws (“forward-looking statements”) about JWC and its business and operations which include, among other things, statements regarding the production of cannabis at JWC’s second facility, increased production capacity and participation of the Corporation in the recreational cannabis market. The forward-looking statements can be identified by the use of such words as “will”, “expected”, “approximately”, “may”, “could”, “would” or similar words and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to differ materially from those implied in the forward-looking statements. For example, risks include risks regarding the cannabis industry, economic factors, the equity markets generally, building permit related risks and risks associated with growth and competition as well as the risks identified in the Corporation’s Filing Statement available under the Corporation’s profile at www.sedar.com. Although JWC has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and are based on current assumptions which management believes to be reasonable. The Corporation disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information about this release, please contact

Nathan Woodworth, President & CEO of JWC
Email: nathan@jwc.ca
Phone: (519) 594-0144 x421

OR

George Aizpurua, Vice President of First Canadian Capital Corp.
Email: gaizpurua@firstcanadiancapital.com
Phone: (416) 742-5600

VANCOUVER, British Columbia, March 29, 2019 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has fulfilled its first purchase order of cannabis from Yukon Liquor Corporation, signed a sales agreement with Alberta Gaming, Liquor and Cannabis (AGLC), and become officially registered by the Saskatchewan Liquor and Gaming Authority (SLGA) to supply cannabis to the Saskatchewan market. First shipments to Alberta and Saskatchewan are expected in April.

“We are pleased to provide our Emerald-branded cannabis products to the adult-use markets in Alberta, Saskatchewan and the Yukon,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “This brings the number to five provinces and one territory across Canada and is another step in our sales strategy to become a reliable national recreational cannabis supplier.”

Emerald is consistently meeting its supply commitments in Ontario, British Columbia, and Newfoundland and Labrador, and is advancing prospective supply agreements with all remaining provinces and territories in order to develop a significant presence in the recreational market.

Emerald’s cannabis supply is provided by its Verdélite indoor facility in Saint Eustache, Québec, and Pure Sunfarms, its 50%-owned joint venture in BC that is licensed to cultivate in 1.03 million square feet of its 1.1 million square foot greenhouse. This facility has been scaling up production over the last four quarters and will be fully planted in April. Emerald is working to expand sources and volume of indoor, greenhouse and outdoor-grown cannabis and hemp. In 2018, Emerald acquired 500 acres of harvested hemp and expects to purchase 1,000 acres of harvested hemp in 2019.

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics is a Canadian licensed producer of cannabis with operations in British Columbia and Québec. Emerald has secured exclusive strategic partnerships for large scale extraction and softgel encapsulation, as well as for proprietary technology to enhance cannabinoid bioavailability. Its team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers.

Emerald is part of the Emerald Group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Please visit www.emeraldhealth.ca for more information or contact:

Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. # 5

Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include projected job creation figures at our operating facilities; production and processing capacity of various facilities; expansion of facilities; and anticipated production costs.

We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management’s current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

NEW YORK and TORONTO, March 29, 2019 /PRNewswire/ – iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN, OTCQX: ITHUF), which owns, operates, and partners with best-in-class regulated cannabis operations across the United States, is pleased to announce that its U.S. subsidiary has entered into a letter of intent to acquire CBD For Life, a top-ranked, national CBD brand in the U.S.

CBD For Life was launched in February of 2016 by its co-founders Beth Stavola and Julie Winter, who are well-recognized as leaders and innovators in the cannabis and CBD industries. Beth Stavola is being featured as an honoree this year for the “2019 High Times Women of Weed” and was recognized as Inc.com’s “Top 100 Female Founders” in 2018. The brand’s CBD-infused pain management and beauty products have been featured in a wide range of online and print publications including Forbes, Shape, Marie Claire, Women’s Health, Cosmopolitan and Allure. CBD For Life’s product lineup has also been featured in stories by multiple broadcast news outlets in the New York City metro area and its products have received numerous accolades including the 2018 Skincare Award Winner for the Hollywood Beauty Awards “Product of the Year”.

CBD For Life has experienced an increase in interest from mainstream retailers in the first quarter of 2019 following the passage of the Farm Bill. Products are available directly to consumers online and CBD For Life is currently distributing to 750 retail locations and actively on-boarding approximately 25 new locations per week with a dedicated sales channel working with national retailers. The currently available product lineup includes:

• Health and Wellness – CBD-infused topicals, tinctures and sprays made for targeted pain relief ranging from muscle soreness to head-aches
• Beauty and Skincare – Formulas blending essential oils and CBD extract into lotions, creams, and hair products designed to improve rejuvenation and restore moisture

These products are designed for self-care, beauty, and wellness; and through a partnership with iAnthus, CBD For Life plans to expand its existing wholesale and retail platform to give more consumers access to its growing range of products.

“Developing a strong CBD strategy is mission critical for cannabis companies to compete on a national scale while simultaneously entering the consumer product and retail marketplace,” said Hadley Ford, Chief Executive Officer of iAnthus. “With the acquisition of a name brand like CBD For Life, iAnthus is well positioned to increase our market share with greater exposure to patients and customers across the country.”

According to industry experts, retail sales of CBD consumer products are estimated to have been between US$600 million and US$2 billion in 2018. As a growing number of CBD brands and product types become increasable available through diverse retail channels, the CBD market is projected to generate US$16 billion in retail sales by 2025. Research has shown that nearly 7% of the U.S. population in January of 2019 reported using CBD as a supplement, and that number is expected to grow to at least 10% by 2025¹.

“We’re excited to bring CBD For Life into the iAnthus family—our CBD brand will provide iAnthus with even greater reach and a wider consumer base, particularly in states that have yet to implement full-scale cannabis programs,” said Beth Stavola, Co-Founder of CBD For Life and Chief Strategy Officer of iAnthus.

Fairness Opinion and Proposed Structure

iAnthus expects to acquire 100% of the equity interests in CBD For Life in return for 2,529,863 common shares of iAnthus. Based on a fixed share price of US$5.41 (the closing price of ITHUF shares on the OTCQX as of March 15, 2019), the stock consideration equates to US$13.7 million. At the closing of the transaction, iAnthus also expects to repay the outstanding debt and related accrued interest of CBD For Life in the amount of approximately US$2.0 million in cash.

The transaction with CBD For Life is a “related party transaction” as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“) due to the fact Beth Stavola is an officer and director of iAnthus and an officer and significant shareholder of CBD For Life. iAnthus expects to rely on an exemption from the formal valuation and minority shareholder approval requirements of MI 61-101 based on a determination that the securities of the Company are listed on the Canadian Securities Exchange (“CSE“) and that the fair market value of the transaction, in so far as it involves an interested party, does not exceed 25% of iAnthus’ market capitalization.

Notwithstanding the fact that the transaction with CBD For Life is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101, iAnthus engaged GMP Securities L.P. to provide a fairness opinion to the members of the Board of Directors who are non-related parties (the “Fairness Opinion“). iAnthus expects that the Fairness Opinion, subject to the assumptions, limitations, and qualifications set forth therein, will conclude that the consideration to be paid by iAnthus for the acquisition of CBD For Life is fair, from a financial point of view, to iAnthus.

Closing of the transaction with CBD For Life is subject to the parties entering into a definitive agreement and that iAnthus receives the Fairness Opinion. The parties expect to enter into a definitive agreement in the second quarter of 2019. There can be no assurances that the transaction the transaction will be completed as proposed or at all.

About iAnthus Capital Holdings, Inc.

iAnthus Capital Holdings, Inc. owns and operates best-in-class licensed cannabis cultivation, processing and dispensary facilities throughout the United States, providing investors diversified exposure to the U.S. regulated cannabis industry. Founded by entrepreneurs with decades of experience in operations, investment banking, corporate finance, law and health care services, iAnthus provides a unique combination of capital and hands-on operating and management expertise. iAnthus currently has operations in 11 states, and operates 21 dispensaries (AZ-4, MA-1, MD-3, FL-3, NY-2, CO-1, VT-1 and NM-6 where iAnthus has minority ownership). For more information, visit www.iAnthusCapital.com.

About CBD For Life

CBD For Life is a producer of highly innovative, natural, luxurious, and effective Cannabidiol (CBD) infused pain management and beauty products using 99% pure CBD extract derived from stems and stalks of industrial hemp. Its revolutionary formulas combine CBD with nourishing essential oils and other active ingredients to aid in reducing pain, inflammation, and stress while promoting anti-aging, rejuvenation, and vibrancy. CBD For Life is headquartered in New Jersey where the products are produced in a large-scale contract manufacturing facility. CBD For Life’s products include pure body rubs, pure roll on oils, pure sprays, infused bath bombs, tinctures, creams, lotions, lip balm, and hair care products. All CBD For Life products are 95% naturally derived and are free of GMO’s, parabens, phthalates, formaldehyde, artificial coloring and are never tested on animals. For more information, visit www.cbdforlife.us.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in iAnthus’ periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should, our vision” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements including the expected date that CBD For Life and iAnthus will enter into a definitive agreement for the transaction, the proposed terms of the definitive agreement with CBD For Life, iAnthus’ receipt of the Fairness Opinion and other statements of fact.

Readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. iAnthus disclaims any intention or obligation to update or revise such information, except as required by applicable law, and iAnthus does not assume any liability for disclosure relating to any other company mentioned herein.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

SOURCE iAnthus Capital Holdings, Inc.

Related Links

https://www.ianthuscapital.com/

TORONTO, March 28, 2019 (GLOBE NEWSWIRE) — Flower One Holdings Inc. (the “Company”) (CSE: FONE) (OTCQB: FLOOF), a leading cannabis cultivator, producer and innovator in Nevada,  is pleased to announce the closing of its previously announced overnight marketed public offering (the “Offering”) of unsecured convertible debenture units of the Company (the “Debenture Units”) for aggregate gross proceeds of $50,000,000.  In connection with the Offering, the Company issued a total of 50,000 Debenture Units at a price of $1,000 per Debenture Unit (the “Offering Price”).

As part of the Offering, the Agents (as defined below) have been granted an over-allotment option (the “Over-Allotment Option”) for up to 30 days after the Closing in respect of: (i) additional Debenture Units (each an “Over-Allotment Unit”); (ii) additional Convertible Debentures (each an “Additional Debenture”) at a price of $824.51 per such Additional Debenture; (iii) additional Warrants (each an “Additional Warrant”) at a price of $0.9140 per Additional Warrant; or (iv) any combination thereof; provided that the aggregate number of Additional Debentures and Additional Warrants which may be issued under the Over-Allotment Option (including those comprising Over-Allotment Units) does not exceed 7,500 Additional Debentures or 1,440,000 Additional Warrants, respectively.

“The success of this offering highlights the strong interest from investors and their increased confidence in the execution of our business model and strategy,” said Ken Villazor, President and CEO of the Company. “This funding better positions Flower One to capitalize on the continued growth and opportunities in Nevada and solidify our initial entry into the U.S. cannabis market as we continue to develop our best-in-class production facility.”

The Offering was completed pursuant to an agency agreement (the “Agency Agreement”) dated March 22, 2019 with Mackie Research Capital Corporation and Canaccord Genuity Corp. (collectively, the “Lead Agents”), on behalf of a syndicate of agents including Cormark Securities Inc., Eight Capital, Industrial Alliance Securities Inc., and PI Financial Corp. (together with the Lead Agents, the “Agents”).

The net proceeds received by the Company from the Offering are intended to be used for the payment of outstanding notes, ongoing construction and development of its Nevada production facility, working capital and general corporate purposes.

Each Debenture Unit consists of one 9.5% unsecured convertible debenture (the “Convertible Debentures“) maturing three years from the date of issuance and 192 common share purchase warrants of the Company (the “Warrants“). The Convertible Debentures shall bear interest at a rate of 9.5% per annum from the date of issue, payable semi-annually in arrears on the last day of June and December in each year and will have a maturity 36 months from the date of issuance (the “Maturity Date”). The principal amount of each Convertible Debenture shall be convertible, for no additional consideration, into common shares of the Company (“Common Shares“) at the option of the holder at any time prior to the earlier of: (i) the close of business on the Maturity Date, and (ii) the business day immediately preceding the date specified by the Company for redemption of the Convertible Debentures upon a change of control at a conversion price equal to $2.60 (the “Conversion Price”), subject to certain adjustment and acceleration provisions.  Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $2.60 at any time up to 36 months following Closing of the Offering.

Pursuant to the terms of the Agency Agreement, the Company paid the Agents a cash commission equal to 6.0% of the gross proceeds of the Offering, and issued to the Agents 999,936 non-transferable warrants (the “Broker Warrants“) of the Company, each such Broker Warrant exercisable into a Common Share at an exercise price of equal to the Conversion Price per Common Share exercisable at any time up to 36 months from the Closing Date.

The Convertible Debentures and the Warrants have been approved for listing with the Canadian Securities Exchange under the symbols FONE.DB and FONE.WT, respectively and will begin trading on the Closing Date.

The Offering is being made pursuant to a short-form prospectus filed in each of the provinces of Canada (except Québec), and otherwise by private placement exemption in those jurisdictions where the Offering can lawfully be made, including the United States.  Neither the Debentures Units (and the Convertible Debentures and the Warrants forming part of the Debenture Units) have been or will be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and such securities may therefore not be offered or sold in the United States or to or for the account or benefit of a person in the United States or a U.S. Person (as defined in Regulation S of the U.S. Securities Act) absent registration or an exemption from the registration requirements including to Institutional Accredited Investors pursuant to Rule 506(b) of Regulation D of the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Debenture Units in any jurisdiction in which such offer, solicitation or sale would be unlawful. Three subscribers in the United Kingdom entered into a placing letter and settled 400 Debenture Units directly with the Company.  In connection with this, the Agents received a cash compensation equal to 6.0% of the gross proceeds and no Broker Warrants.  A copy of the short form prospectus dated March 22, 2019 is available under the Company’s profile on SEDAR at www.sedar.com.

About Flower One Holdings Inc.

Flower One is sharply focused on quickly becoming the leading cannabis cultivator, producer and innovator in the highly lucrative Nevada market. Flower One owns and operates a 25,000 square-foot cultivation and production facility in North Las Vegas, with nine grow rooms, and owns the established NLV Organics consumer brand of cannabis products. The Company is also rapidly converting its 455,000 square-foot greenhouse and production facility, which is the largest in the State of Nevada, for cultivating and processing high-quality cannabis at scale. Combined, the flagship greenhouse facility and production facility (once fully operational) and the North Las Vegas facility provide Flower One with 480,000 square feet of capacity for cultivation and processing, production and high-volume packaging of dry flower, cannabis oils, concentrates and infused products. The Company is fully licensed for medical marijuana cultivation and production, as well as recreational marijuana cultivation and production in the state of Nevada and currently holds licensing agreements with their Brand Partners, Flyte Concentrates, Rapid-Dose Therapeutics’ Quick Strip, Old Pal, Palms, HUXTON, CannAmerica Brands and G Pen.

The Common Shares are traded on the Canadian Securities Exchange under the Company’s symbol “FONE” and in the United States on the OTCQB under the symbol “FLOOF.” For more information, visit: https://flowerone.com

For inquiries please contact:

Flower One Holdings Inc.
Ken Villazor, President and CEO
416.200.7641
kvillazor@flowerone.com

Flower One investor relations inquiries
NATIONAL Capital Markets
416.848.9835
ir@flowerone.com

Flower One media inquiries
Natalie Martin
604.738.2220
flowerone@talkshopmedia.com

The CSE does not accept responsibility for the adequacy or accuracy of this press release.

Forward Looking Statements
                                                           
Statements in this press release that are not statements of historical or current fact constitute “forward looking information” within the meaning of Canadian securities laws and “forward looking statements” within the meaning of United States securities laws (collectively, “forward-looking statements”). Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue” or other similar expressions to be uncertain and forward looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Forward-looking statements in this press release include, but are not limited to, the use of the net proceeds of the Offering; information or statements about the Company’s strategy; future operations, prospects and the plans of management; the Company’s ability to achieve its objectives and plans, including the timing and results of those objectives; the timing and extent of the conversion of its 455,000 square foot greenhouse and production facility in Nevada; the Company’s potential to become the leading cannabis cultivator, producer and innovator in the Nevada market; the scale and capacity of the Company’s cultivation, processing and high-volume packaging facilities in Nevada; and the Company’s ability to fund its continued operations.

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational and medicinal cannabis marketplaces in the United States through its subsidiary Cana Nevada Corp. Local state laws where Cana Nevada Corp. operates permit such activities; however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Corporation’s business are contained under the heading “Risk Factors” in the Company’s annual information form dated November 7, 2018 filed on its issuer profile on SEDAR at www.sedar.com.

Although the Company has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: the Company’s dependence on obtaining regulatory approvals; investing in target companies or projects that are engaged in activities currently considered illegal under United States federal law; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change.

The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement, the “Forward-Looking Statements” section contained in the Company’s most recent management’s discussion and analysis (“MD&A”), which are available on SEDAR at www.sedar.com. All forward-looking statements in this press release are made as of the date of this press release. The Company does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in the Company’s public securities filings with the Canadian securities commissions, including the Company’s most recent MD&A.

BOULDER, CO, March 28, 2019 /PRNewswire/ – Charlotte’s Web Holdings, Inc. (“Charlotte’s Web” or the “Company”) (CSE:CWEB, OTCQX:CWBHF), the market share leader in hemp-derived CBD extract products, today reported financial results for the fourth quarter and year ended December 31, 2018. All amounts are expressed in United States dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS measures.

Highlights of Fourth Quarter 2018 Results versus Fourth Quarter 2017 Results

• Organic consolidated revenue growth of 71% to $21.5 million (up 21% QoQ)
• Gross profit increased 63% to $16.3 million, or 76% of consolidated revenue
• Adjusted EBITDA decreased from 37% to 20% of consolidated revenue, due to extraordinary items
• Retail doors increased more than 80% to 3,680 at December 31, 2018
• 57% of revenue from eCommerce
• 2018 Farm Bill passed on December 20, 2018 removing hemp from the Federal CSA and designating it as an agricultural commodity governed by the USDA and FDA

Highlights of 2018 Full Year Results versus Full Year 2017 Results

• Organic revenue growth of 74% to $69.5 million
• Gross profit increased 75% to $52.3 million, or 75% of consolidated revenue
• Adjusted EBITDA decreased from 36% to 30% of consolidated revenue

Highlights Subsequent to December 31, 2018

• Executive leadership expansion with COO and CGO additions
• Record harvest of 675,000 pounds securing inventory to meet future demand
• Hemp Authority Certification received
• FDA commits to working with hemp industry on hemp product regulations
• First product orders shipped to three national retail grocery and drug chains in select locations

At the end of the fourth quarter the 2018 Farm Bill was successfully passed by U.S. Congress, providing the needed clarity and catalyst for expansion of the hemp industry. “We believe this important legislation will have a positive impact on consumer access to hemp-derived CBD products and for our valuable farming communities throughout the country,” said Hess Moallem, President and Chief Executive Officer.

“During the fourth quarter we concentrated our efforts on completing the 2018 harvest and building product inventory to support growing consumer demand,” said Mr. Moallem.  “Our 2018 harvest resulted in 675,000 pounds of raw hemp compared to 63,000 pounds in 2017. The record harvest benefited from excellent growing conditions and the unique expertise we’ve accumulated over the past five years of cultivating the complex hemp plant. This inventory build ensures we are able to meet growing demand and supply the large national retail chains that are beginning to carry our products.”

Product sales increased year-over-year with human nutrition products, topicals and animal nutrition products growing by 76%, 1085% and 189%, respectively. (The canine line is growing from a smaller base as it was launched in February of 2018.) “In general, broader consumer awareness of the benefits of cannabinoids, namely cannabidiol (CBD) from hemp extract, is driving increased uptake in all product categories in our retail channels and e-commerce platform,” added Mr. Moallem.

The Company has been actively adding additional retail distribution customers and locations. Initially available in natural health stores throughout the United States, increased education and understanding of hemp extract has been driving demand for Charlotte’s Web products through ever larger retail chains. The Company recently surpassed 4,000 locations after national retail chains began carrying Charlotte’s Web products.  Today, Charlotte’s Web can be found on the shelves at a growing number of national brand grocery and drug chains in select stores and states.

Charlotte’s Web is the market leader in the rapidly expanding hemp-derived CBD wellness markets, dedicated to producing the highest quality products and efficacy. Several new products and formats are planned for 2019 in animal nutrition, wellness topicals and human consumables.

Fourth Quarter and Year-to-Date 2018 Results

The following table sets forth selected financial information for the periods indicated.

The following information sets forth selected quarterly revenue information for the Company’s eight most recent fiscal quarters.

Revenue for the quarter ended December 31, 2018 (Q4-2018) totaled $21.5 million, compared to $12.6 million for the same period in 2017, representing a 71% increase. On a year-over-year basis for Q4-2018, e-commerce revenue grew by 58% and wholesale, distributor and retail revenue grew by 76%. During Q4 2018 and 2017, e-commerce sales accounted for 57% and 59% of total sales, respectively. Revenue from human nutrition products, topicals and animal nutrition products grew by 73%, 373% and 126%, respectively (the Company’s canine products were introduced in February of 2017).

Revenue for the year 2018 totaled $69.5 million, compared to $40.0 million for 2017, representing a 74% increase. On a year-over-year basis for 2018, e-commerce revenue grew by 51% and wholesale, distributor and retail revenue grew by 126%. For 2018, revenue from human nutrition, topical and canine products grew by 76%, 1085% and 189%, respectively. The Company’s topical and canine products each accounted for approximately 4% of total revenue during 2018.

Gross profit totaled $16.3 million for Q4- 2018, compared to $10.0 million for the same period in 2017, a year-over-year increase of 63%. As a percent of total revenue, gross profit in Q4-2018 was 76%, compared to 80% for the same period in 2017.

Gross profit totaled $52.3 million for 2018, compared to $29.9 million for the same period in 2017, a year-over-year increase of 75%. As a percent of total revenue, gross profit for 2018 and 2017 was 75%.

For Q4-2018 and Q4-2017, sales and marketing expenses were $4.4 million and $1.7 million, respectively (year-to-date $12.8 million and $5.9 million, respectively). As a percent of revenue, sales and marketing expenses for the quarters ending Q4-2018 and Q4-2017 were 20.6% and 13.5%, respectively (year-to-date 18.4% and 14.8%, respectively).

For Q4-2018 and Q4-2017, general and administrative expenses were $8.1 million and $4.2 million, respectively (year-to-date $22.3 million and $11.5 million, respectively). As a percent of revenue, general and administrative expenses for the quarters ending Q4-2018 and Q4-2017 were 37.7% and 33.4%, respectively (year-to-date 32.1% and 28.7%, respectively). General and administrative expenses during Q4-2018 included non-recurring expenses for legal related expenditures associated with regulatory activities (both domestic and international), governance and securities related activities associated with its recent public company status. Combined, these extraordinary expenses resulted in Adjusted EBITDA margins for the quarter below the Company’s historical average.  While growth and margins may vary quarterly, management anticipates Adjusted EBITDA to generally be within 30% to 35% of revenue on an annualized basis, in line with its historical norms.

Net Income for Q4-2018 was $3.2 million, or $0.03 per share, (year-to-date $11.8 million or $0.14 per share) compared to $2.4 million, or $0.03 per share, (year-to-date $7.5 million or $0.09 per share) during the same period in 2017. Excluding IPO related costs of $1.3 million in 2018, net income for the year was $13.1 million, or $0.16 per share, a 76% year-over-year increase.

Adjusted EBITDA¹ as a percentage of consolidated revenue for Q4-2018 and Q4-2017 was 20% and 37%, respectively. For the year 2018 and 2017, adjusted EBITDA as a percentage of consolidated revenue was 30% and 36%, respectively.

Balance Sheet and Cash Flow

The Company used $2.4 million of cash in operations during Q4-2018 compared to $2.7 million of cash provided from operations during Q4-2017. The reduction in cash flows from operations primarily reflects the investment in inventory associated with the 2018 hemp crop and other raw materials used in the production process in anticipation of materially increasing revenue opportunities. The Company’s cash at December 31, 2018 was $73.4 million compared to $7.1 million on December 31, 2017. Working capital at December 31, 2018 was $93.8 million.

Consolidated Financial Statements and Management’s Discussion and Analysis

The Company’s audited consolidated annual financial statements and accompanying notes for the years ended December 31, 2018  and 2017 and related management’s discussion and analysis of financial condition and results of operations (“MD&A”) are available under the Company’s profile on SEDAR at www.sedar.com and on the Investor Relations section of the Company’s website at https://investors.cwhemp.com.

Conference Call

Management will host a conference call to discuss the Company’s fourth quarter and annual 2018 results at 8:30 am ET on Friday, March 29, 2019. To participate in the call, please dial 1-647-427-7450 or 1-888-231-8191 approximately 10 minutes before the conference call and provide conference ID 3092088. A recording of the call will be available through April 5, 2019. To listen to the rebroadcast please dial 1-416-849-0833 and provide the same conference ID.

A webcast of the call can be accessed through the investor relations section of the Charlotte’s Web website.

About Charlotte’s Web Holdings, Inc.

Charlotte’s Web Holdings, Inc. is the market leader in the production and distribution of innovative hemp-derived cannabidiol (“CBD”) wellness products. Founded by the Stanley Brothers, the Company’s premium quality products start with proprietary hemp genetics that are responsibly manufactured into hemp-derived CBD extracts naturally containing a full spectrum of phytocannabinoids, including CBD, terpenes, flavonoids and other beneficial hemp compounds. Industrial hemp products are non-intoxicating. Charlotte’s Web product categories include CBD Oil tinctures (liquid products), CBD capsules, CBD topicals, as well as CBD pet products.  Charlotte’s Web hemp-derived CBD extracts are sold through select distributors, brick and mortar retailers, and online through the Company’s website at www.CharlottesWeb.com. The rate the Company pays for agricultural products reflects a fair and sustainable rate driving higher quality yield, encouraging good farming practices, and supporting U.S. farming communities.

Charlotte’s Web is a socially conscious company and is committed to using business as a force for good and a catalyst for innovation. The Company weighs sound business decisions with consideration for how its efforts affect its employees, customers, the environment, and the communities where its employees live and where it does business, while maximizing profits and strengthening its brands. The Company’s management believes that socially oriented actions have a positive impact on the Company, its employees and its shareholders. Charlotte’s Web donates a portion of its pre-tax earnings to charitable organizations.

Shares of Charlotte’s Web trade on the Canadian Securities Exchange under the symbol “CWEB” and in the United States on the OTCQX under the symbol “CWBHF”.  Charlotte’s Web has 24,095,294 Common Shares outstanding and 172,896.15 Proportionate Voting Shares convertible at 400:1, for an effective equivalent of 93,253,754 Common Shares outstanding.

Forward-Looking Information

This press release may contain forward-looking information within the meaning of applicable securities legislation. In the interest of providing the shareholders and potential investors of Charlotte’s Web Holdings, Inc. with information about the Company and its subsidiaries, including management’s assessment of the Company and its subsidiaries’ future plans and operations, certain information provided in this press release constitutes forward-looking statements or information (collectively, “forward-looking statements”). Forward-looking statements are typically identified by words such as “may”, “will”, “should”, “could”, “anticipate”, “expect”, “project”, “estimate”, “forecast”, “plan”, “intend”, “target”, “believe” and similar words suggesting future outcomes or statements regarding an outlook. Although these forward-looking statements are based on assumptions the Company considers to be reasonable based on the information available on the date such statements are made, such statements are not guarantees of future performance and readers are cautioned against placing undue reliance on forward-looking statements. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties, and other factors which may cause actual results, levels of activity, and achievements to differ materially from those expressed or implied by such statements. The forward-looking information contained in this press release is based on certain assumptions and analysis by management of the Company in light of its experience and perception of historical trends, current conditions and expected future development and other factors that it believes are appropriate.

The Company’s forward-looking statements are subject to risks and uncertainties pertaining to, among other things, revenue fluctuations, nature of government regulations, economic conditions, loss of key customers, retention and availability of executive talent, competing products, common share price volatility, loss of proprietary information, product acceptance, internet and system infrastructure functionality, information technology security, cash available to fund operations, availability of capital and, international and political considerations, including but not limited to those risks and uncertainties discussed under the heading “Risk Factors” in the MD&A and the Company’s other filings with securities regulators. The impact of any one risk, uncertainty, or factor on a particular forward-looking statement is not determinable with certainty as these are interdependent, and the Company’s future course of action depends on Management’s assessment of all information available at the relevant time. Except to the extent required by law, the Company assumes no obligation to publicly update or revise any forward-looking statements made in this press release, whether as a result of new information, future events, or otherwise. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on the Company’s behalf, are expressly qualified in their entirety by these cautionary statements.

SOURCE Charlotte”s Web Holdings, Inc.

Venture capital group announces the launch of its new fund, Hypur Ventures II, that will invest up to $500MM into the legal cannabis industry

SCOTTSDALE, AZ / ACCESSWIRE / March 28, 2019 / HypurVentures, a leading venture capital fund dedicated to investing in the legal cannabis industry, announced the launch of its new fund,Hypur Ventures II. The fund is managed by Hypur Ventures II GP, LLC whose members have been operating and investing in the legal cannabis industry since 2012.

Leveraging its extensive industry experience, Hypur Ventures II will invest across the complex cannabis and hemp supply chain. The objective of Hypur Ventures II is to strategically enhance value through investments in well-managed, revenue-generating businesses. A portion of the Hypur Ventures II portfolio will focus on mergers, acquisitions and rollup opportunities. Hypur Ventures II plans to invest in private companies with seasoned operators to provide growth and acquisition capital for initiatives at various stages of maturity. Fund investments may range between $1 million to $25 million. The maximum size of Hypur Ventures II will be $500 million.

“We are confident that by investing in experienced operators and companies with strong growth and defensible business models, we have an opportunity to unlock value in one of the fastest growing industries in the world today,” says Founder and Managing Director, Christopher E. Galvin. “With the anticipated opening of the US public markets over the next 18-24 months, we expect to see significant levels of accelerating growth and long-term sustainable sector interest.”

As the industry evolves, Hypur Ventures’ second fund expects to make more investments into the industry’s infrastructure and enterprise technology businesses that support the sector. The firm will also look to qualified international markets for investment opportunities, particularly as more countries in Europe and South America introduce legislation to legalize cannabis.

About Hypur Ventures II

Hypur Ventures II is a venture capital fund dedicated to helping cannabis businesses fuel growth, gain market share, and create long-term value across the industry’s supply chain.

Forward Looking Statements

This press release may contain “forward-looking” information or statements. These statements include, but are not limited to, discussions related to the expectations of Hypur Ventures II regarding the prospective performance of its investment strategy and other non-historical statements. All forward-looking statements are based on the beliefs and assumptions ofHypur Ventures management relative to currently available information. There can be no assurance that such forward-looking statements will be accurate. Actual results and future events could differ materially from those anticipated in such statements. For purposes of this release, the words “believe,” “anticipate,” “estimate,” “expect,” “intend” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to certain risks, uncertainties and assumptions. Such risks include prospective investments and acquisitions by Hypur Ventures II of portfolio companies which under US Federal laws may be construed as engaging in illegal activity. Other risks may include, but are not limited to, significant competition, potential adverse public opinion, dependence on key personnel, volatility of markets, management of growth, tax regulations which prohibit the deductibility of cannabis-related business expenses, variability of revenues, net income and cash flow, and litigation risks, among others. Hypur Ventures II undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances or to reflect unanticipated events or developments.

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Subscription for the purchase of limited partnership interests of Hypur Ventures II is open only to accredited investors under Rule 506(c) of Regulation D promulgated by the SEC under the Securities Act of 1933, as amended.

Additional Links

For more information on Hypur Ventures II

SOURCE: Hypur Ventures

VAUGHAN, ON, March 28, 2019 /CNW/ – CannTrust Holdings Inc. (“CannTrust” or the “Company”, TSX:TRST,NYSE: CTST) today released its financial results for the fourth quarter and year ended December 31, 2018.

“The CannTrust team has delivered remarkable growth in the fourth quarter of 2018. We achieved record sales volume, record revenue and our medical patient count continues to increase, reflecting the quality of our products and customer service,” said Peter Aceto, Chief Executive Officer.

“We expect the trajectory of revenue growth to continue in 2019 as we bring additional capacity online through our Phase 2 expansion, realize the potential of investments we have made into training and crop yield optimization, implement targeted price increases and distribute our products to more and more consumers. Additionally, CannTrust expects to take bold action to achieve leadership in growing cannabis outdoors. We have entered into Letters of Intent to secure approximately 200 acres of land, which we estimate will add an additional 100,000kg to 200,000kg of production in 2020, subject to regulatory approvals. In combination with our Phase 3 expansion, we estimate our annual production capacity target to be between 200,000kg and 300,000kg. We also plan to become an early-mover in vaporization products and develop further partnerships to bring innovative products to market. These initiatives are the result of thoughtful and calculated work the Company has performed in assessing its growth strategy. This is truly a very exciting time for CannTrust,” continued Mr. Aceto.

Fourth Quarter 2018 Highlights

• CannTrust reported record revenue of $16.2 million, a 132% increase from the fourth quarter of 2017.
• Active patient count increased to 58,000, up from 37,000 at the end of the prior year, an increase of 57%.
• The Company sold 3,407kg of dried cannabis equivalent, a 4.5x increase from 758kg in the fourth quarter of 2017.
• Cash costs per gram decreased to $2.94 from $5.16 in the fourth quarter of 2017.
• CannTrust was voted Top Licensed Producer of the year and received six other service and product awards at the 2018 Canadian Cannabis Awards.
• The Company closed the purchase of a 19.4 acre property on land adjacent to its Perpetual Harvest Facility in the Town of Pelham, which will be used to construct its Phase 3 expansion and bring total production capacity to 100,000kg per year upon its completion.

Fourth Quarter and Year Ended 2018 Financial Summary
Selected Information
(CDN $000’s, except per share amounts and unless otherwise noted)

Net revenue for the fourth quarter of 2018 increased to $16.2 million from $7.0 million in the fourth quarter of 2017. The increase in revenue was attributable to increased sales volumes primarily due to the continued growth in the Company’s medical patient base and sales derived from the recreational market in Canada. The growth in sales volume was partially offset by the absorption of excise taxes on our medical products beginning in the fourth quarter of 2018, which impacted revenue by $0.9 million.

Gross profit before changes in fair value of biological assets increased to $5.7 million in the fourth quarter of 2018 from $2.4 million in the prior year, reflecting growth in medical and recreational revenue. Gross margin before fair value changes to biological assets declined from 69% in the third quarter of 2018 to 35% in the fourth quarter, as a result of absorption of the excise tax on medical sales, lower pricing on wholesale sales and the impact of not yet operating at full production capacity during the quarter.

Adjusted EBITDA declined to a loss of $8.5 million in the fourth quarter of 2018, compared to a loss in the comparable period of the prior year of $0.9 million. During the quarter, the Company made deliberate investments in operating expenses in support of its growth efforts. Specifically, these investments included marketing costs to support the launch of four recreational brands, personnel to advance product innovation and our international strategy, and costs in preparation of the Company’s listing on the New York Stock Exchange.

As at December 31, 2018, CannTrust remained in a strong financial position with $72.0 million in cash and short term investments, and a working capital position of $111.6 million.

Events Subsequent to Year End 2018

• The Company obtained all necessary permits from the Town of Pelham for the construction of its 390,000 square foot Phase 3 expansion.
• Greg Guyatt was appointed Chief Financial Officer.
• The Company’s common shares began trading on the New York Stock Exchange under the ticker symbol “CTST”.
• CannTrust was included in the TSX Composite Index.
• Entered into Letters of Intent to secure approximately 200 acres of land through purchase and lease. The Company plans to use this land for outdoor harvest of cannabis using its proprietary genetics. These transactions are expected to close in the second quarter of 2019, subject to customary closing conditions.
• Made capital investments to enhance the Company’s extraction equipment, which the Company believes will triple its annual capacity.

Outlook

CannTrust expects to continue to make investments in a disciplined and deliberate manner to position the Company to take advantage of future opportunities, both domestically and internationally. The Company continues to invest in people, process, technology and marketing, and is developing innovative products for the expected legalization of the edibles market in Canada later in 2019. These products include vape pens, beverages and confectionaries. CannTrust is also making strategic investments into its capacity to prepare for expected increases in demand for its products. The Company believes it will be a leader in outdoor growing capability, which will leverage its proprietary genetics and has the potential to accelerate the Company’s low-cost production advantage.

The completed Phase 2 expansion of the Perpetual Harvest Facility is expected to increase production capacity to 50,000kg on an annualized basis. With this increased production capability, the Company believes revenue will increase significantly in 2019 compared to the 2018 full year results, with revenue growth accelerating throughout the year starting in the second quarter of 2019. The Company is positioned to receive all necessary regulatory approvals to support this planned growth. In addition, having obtained all necessary permits from the Town of Pelham for the construction of its Phase 3 expansion, the Company continues to expect its Perpetual Harvest Facility capacity to reach 100,000kg on an annuallized basis in the second half of 2020.

Driving further capacity enhancement for primarily extraction-based products, CannTrust’s outdoor growing initiatives are targeted to deliver material future revenue contributions as early as 2020. The Company estimates the production from this initiative to result in an additional 100,000kg to 200,000kg of cannabis in 2020 subject to regulatory approvals.

CannTrust’s investments into people, process, technology and marketing are expected to impact near-term profitability as the Company continues to scale. These are calculated investments that the Company expects will result in increasing yields, lower cost per gram and the advance of the Company’s brand and strategic initiatives. In the first quarter of 2019, adjusted EBITDA is expected to remain consistent with the fourth quarter of 2018. Profitability is expected to improve following the full realization of the increased operational capacity of the Phase 2 expansion. As the Phase 2 expansion contributes to positive operating leverage, the Company is targeting a return to profitability. CannTrust expects that its gross margin before fair value changes to biological assets should increase throughout 2019 as the Company increases its production levels and gains production efficiencies.

Conference Call Details

The Company will hold a conference this morning at 8:00AM ET to discuss the financial results and provide investors with key business highlights. The call will be hosted by Peter Aceto, Chief Executive Officer, and Greg Guyatt, Chief Financial Officer.

Date: March 28, 2019 │ Time: 8:00AM ET

Participant dial-in: (+1) 416 764 8609 or (+1) 888 390 0605

Conference ID: 41347163

Listen to the webcast:

https://event.on24.com/wcc/r/1959823/EE67F27D426445C606A84C145664F6BD

About CannTrust

CannTrust is a federally regulated licensed producer of medical and recreational cannabis in Canada, and the 2018 Canadian Cannabis Awards “Top Licensed Producer of the Year”. Founded by pharmacists, CannTrust brings more than 40 years of pharmaceutical and healthcare experience to the medical cannabis industry and serves more than 67,000 medical patients with its dried, extract and capsule products. The Company operates its 450,000 sq. ft. Niagara Perpetual Harvest Facility in Pelham, Ontario, has been permitted to construct another 390,000 sq. ft. facility in Pelham, and prepares and packages its product portfolio at its 60,000 sq. ft. manufacturing centre of excellence in Vaughan, Ontario.

CannTrust is developing nanotechnology to develop new products in the medical, recreational, beauty, wellness and pet markets. The Company has established its international footprint through a strategic partnership with Cannatrek Ltd. in Australia and a joint venture with STENOCARE in Denmark. The Company has also partnered with Breakthru Beverage Group through Kindred Canada, for recreational distribution in Canada. CannTrust is committed to research and innovation through partnerships with McMaster University in Ontario and Gold Coast University in Australia, which were designed to contribute to the growing body of evidence-based research regarding the use and efficacy of cannabis.

For more information, please visit www.canntrust.ca.

Forward Looking Statements

This press release contains “forward-looking information” within the meaning of Canadian Securities laws and “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and other applicable United States safe harbor laws and such statements are based upon CannTrust’s current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as “believes”, “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy.

The forward-looking information and statements in this news release are based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information and statements includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information and statements necessarily involve known and unknown risks, including, without limitation: risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments in Canada, the United States and elsewhere; the cannabis industry in Canada generally; and, the ability of CannTrust to implement its business strategies.

Any forward-looking information and statements speak only as of the date on which they are made, and, except as required by law, CannTrust does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for CannTrust to predict all such factors. When considering these forward-looking information and statements, readers should keep in mind the risk factors and other cautionary statements in CannTrust’s Annual Information Form dated March 29, 2018 (the “AIF”) and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com and filed as an exhibit CannTrust’s Form 40-F annual report under the United States Securities Exchange Act of 1934, as amended, with the United States Securities and Exchange Commission on EDGAR at www.sec.gov. The risk factors and other factors noted in the AIF could cause actual events or results to differ materially from those described in any forward-looking information or statements.

The TSX and NYSE do not accept responsibility for the adequacy or accuracy of this release.

SOURCE CannTrust Holdings Inc.

For further information: or to arrange an interview, please contact: Media Relations: Sybil Eastman, Tel: 1-888-677-1477, media@canntrust.ca; Investor Relations: Marc Charbin, 416-467-5229, investor@canntrust.ca

Related Links

https://www.canntrust.ca/

VANCOUVER, March 27, 2019 /CNW/ – Zenabis Global Inc (TSXV:ZENA) (“Zenabis” or the “Company”) is pleased to announce that it has closed its previously announced bought deal private placement of 15,000 unsecured convertible debentures (the “Convertible Debentures“) of the Company, at a price of $1,000 per Convertible Debenture (the “Issue Price“) for gross proceeds of $15,000,000 (the “Offering“). Eight Capital (“Eight Capital“) acted as underwriter of the Offering.

The Company intends to use the net proceeds of the Offering to fund the cost of conversion of its facilities to cannabis production and for working capital.

The Convertible Debentures have a maturity date of September 27, 2021, being 30 months from the date of issue (the “Maturity Date“) and bear interest from the date of issue at 6.0% per annum, payable semi-annually on June 30 and December 31 of each year. The Convertible Debentures are be convertible, at the option of the holder, into common shares of the Company (“Common Shares“) at any time prior to the close of business on the last business day immediately preceding the Maturity Date. The Convertible Debentures have a conversion price of $3.62 per Common Share (the “Conversion Price“).  The purchaser of the Convertible Debentures also received, for no additional consideration, 55 warrants of the Company for every Convertible Debenture purchased (the “Warrants“). Each Warrant is exercisable to purchase one Common Share at an exercise price of $3.62 per share, for a period of 30 months from the date of issue.

The Company may force the conversion of all of the principal amount of the then outstanding Convertible Debentures at the applicable Conversion Price at any time after the date that is four months and one day following the  date of issue of the Convertible Debentures, provided that the Company gives 30 days’ notice of such conversion, which notice may be given at any time after the daily volume weighted average trading price of the Common Shares is greater than a 40% premium to the Conversion Price for any 10 consecutive trading days.

The Convertible Debentures, the Warrants and the Common Shares underlying both, are subject to a statutory hold period which expires on July 28, 2019, being four months and one day following the date of issue of the Convertible Debentures.

As consideration for its services in connection with the Offering, Eight Capital received a cash commission equal to 8.0% of the gross proceeds of the Offering.

In addition, the Company has also entered into an Investment Agreement with three institutional investors (the “Subscribers“), and an Agency Agreement with Eight Capital, pursuant to which Eight Capital has agreed to offer for sale, and the Subscribers have agreed to purchase, an additional 60,000 convertible debentures (the “Additional Debentures“) at the Issue Price, for additional gross proceeds of $60,000,000 (the “Additional Offering“). The Additional Debentures will be issuable in four tranches of $15,000,000, at the option of the Company. Each tranche of Additional Debentures shall have a conversion price equal to a fifteen percent premium to the volume-weighted average price of the Common Shares on the TSX Venture Exchange during the 5 trading-day period immediately preceding the issuance of each tranche of Additional Debentures (the “Additional Debenture Conversion Price“). Each tranche of Additional Debentures will be issuable beginning on the 30^th day following the closing of the most recently issued tranche of Additional Debentures, provided, however, that the Company may decline, in its sole discretion, to issue any Additional Debentures. Purchasers of Additional Debentures will receive, for no additional consideration, that number of warrants that is equal to 20% of the number of Common Shares that an Additional Debenture shall be convertible into (based on the applicable Additional Debenture Conversion Price), at an exercise price that is equal to a fifteen percent premium to the applicable Additional Debenture Conversion Price.  As consideration for its services in connection with the Additional Offering, Eight Capital will receive a cash commission equal to 8.0% of the gross proceeds of the Additional Offering.

About Zenabis

Zenabis is a significant licensed cannabis cultivator of medical and recreational cannabis, and employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta and Langley, B.C.; and Stellarton, Nova Scotia. In addition to gaining technologically advanced knowledge of plant propagation, the recent addition of state-of-the-art greenhouses in Langley provides Zenabis with 3.5 million square feet of facility space that can, upon full conversion, be dedicated to cannabis production.

If all facility space is fully built out and dedicated to production, Zenabis will own, and have access to, 660,000 square feet of high quality indoor cannabis production space, as well as 2.1 million square feet of greenhouse space at its Langley facility (an additional 700,000 square feet of greenhouse space will be used to continue the existing propagation business, to be converted at such a time that is beneficial to the strategic position of the company), strategically positioned on Canada’s coasts. These facilities, if fully converted for cannabis production, would have the design capacity to yield approximately 479,300 kg of dried cannabis annually, for both national and international market distribution. The Zenabis brand name is used among the medical market, while Namaste is used to service the adult-use recreational market.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information

This news release contains statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information may include, among others, statements regarding the future plans, costs, objectives or performance of Zenabis, or the assumptions underlying any of the foregoing. In this news release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. In this news release, forward-looking statements relate, among other things, to: completion of any Additional Offering, the use of the proceeds of the Offering or any Additional Offering, and the design capacity, conversion, expansion and optimization of our facilities. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Zenabis’ control. These risks, uncertainties and assumptions include, but are not limited to, those described Zenabis Management Information Circular dated November 23, 2018, a copy of which is available on SEDAR at www.sedar.com and could cause actual events or results to differ materially from those projected in any forward-looking statements. Furthermore, any forward-looking information with respect to available space for cannabis production is subject to the qualification that management of Zenabis may decide not to use all available space for cannabis production, and the assumptions that any construction or conversion would not be cost prohibitive, required permits will be obtained and the labour, materials and equipment necessary to complete such construction or conversion will be available. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Zenabis does not intend, nor undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws.

For more information, visit: https://www.zenabis.com.

SOURCE Zenabis Global Inc.

For further information: Media Relations, media@zenabis.com, 1-844-523-8679; Investor Relations, Shobana Thaya, Zenabis Global Inc., Invest@zenabis.com, 1-844-523-8679; Andrew Grieve, Chief Executive Officer, 1-855-936-2247

Related Links

https://www.zenabis.com/

TORONTO, March 28, 2019 /PRNewswire-PRWeb/ — Green Tank Technologies, (“Green Tank” or the “Company”) a leading manufacturer of innovative, high-performance vaporization hardware is pleased to announce the completion of its Series A round of financing. The company, launched in 2016 by brothers Dustin and Corey Koffler, secured the CAD $14 million in funding with continued support from existing investors, including Green Acre Capital, coupled with strong demand from new investors including a cornerstone investment by Newstrike Brands, a leading Canadian licensed producer whose strategic partners include Canada’s iconic musicians The Tragically Hip.

The funding comes at a pivotal time for Green Tank, with anticipated revised cannabis regulations coming into effect in late 2019, permitting the legal sale of vapes across Canada. The Company, which experienced annual revenue growth of nearly 300% in 2018, is now working with over 130 brands in the United States and international markets and has signed partnerships with over a dozen licensed producers in Canada including some of the largest in the country. Green Tank also recently announced the launch of a new certified child-resistant vaporizer cartridge, designed exclusively for the cannabis industry. The capital raise will be used to help the Company scale operations, accelerate product innovation, and attract top talent.

According to BDS Analytics, vaping is rapidly becoming the number one cannabis consumption method for recreational and medical use in the United States. In California, vape as a category accounts for roughly 30% of all legal cannabis sales. The appeal of vaporizers, whether it be the discretion they offer, their convenience or the easy entry point they are to new cannabis users, represents a growing trend in the marketplace. Consumer demand, led by vaporizers, is propelling concentrates toward an estimated $8B in retail sales in 2022, outpacing growth in traditional flower sales. Vape sales are expected to hit $6.5B in the same timeframe.

“This financing will enable Green Tank to capitalize on new opportunities on a global scale. It will allow us to achieve our innovation goal of producing the highest performing vape technology on the market and to become the premiere B2B solution for our brand partners around the world,” said Corey Koffler, Green Tank Technologies Chief Operating Officer.

“Our strategic investment in Green Tank underscores our vision of building a premier consumer brand for the adult recreational market, with significant emphasis on the vape category,” said Mark E. Burton, Chief Strategy Officer, Newstrike Brands. “We expect vape products to be a significant part of our overall revenue profile and we are excited to be working closely with Green Tank to design and deliver highly innovative vaporization hardware specifically designed to work seamlessly with our unique cannabis extracts.”

INFOR Financial Inc. acted as financial advisor to Green Tank in respect of the financing.

About Green Tank Technologies
Green Tank Technologies designs, develops and manufactures innovative, high-performance vaporization hardware exclusive to the cannabis industry. The company is committed to providing licensed producers and extractors with state-of-the-art vaporization technology, engineered specifically for each brand’s extract formulations.

SOURCE Green Tank Technologies

VANCOUVER, March 28, 2019 /CNW/ – Choom Holdings Inc. (Choom) (CSE: CHOO; OTCQB: CHOOF) (“Choom”), an emerging adult and medical use cannabis company that has secured one of the largest national retail networks in Canada, is pleased to announce that it has signed a memorandum of understanding (“MOU”) with Better Choice Company, Inc. for the exclusive Canadian distribution rights to Better Choice’s cannabidiol (“CBD”) Bona Vida brand of products targeted for animal health and wellness once approved for sale in Canada. The terms of the MOU are not material.

According to the American Pet Products Association, U.S. pet owners are estimated to have spent over $70 billion in 2018 on pet supplies, treatments and veterinary care.  As CBD pet products become more readily available and accepted, well positioned suppliers and distributors will be able to exploit the tremendous opportunities for growth in the CBD pet sales.

Better Choice Products
Under its Bona Vida brand, Better Choice offers a suite of CBD pet focused products in the form of oils and soft chews with several formulations designed to aid the state of good health and well-being in pets.  Bona Vida has formulations which specifically target animals Relaxation & Heart Support, Muscle & Joint, as well as, Skin & Body.

“We are excited that Better Choice has chosen us as their exclusive distributor in Canada for their pet focused CBD products,” states Chris Bogart, President and CEO of Choom. “We recognize the importance of growing our brand portfolio and having the sole distribution rights for Better Choice products helps us achieve that in an entirely new market on the horizon in pet use products.  From what we know of in the United States, the CBD products for pet use market has proven to be a high margin business. As the normalization of cannabis-based products in Canada grows, consumers will begin to shift towards these new natural alternative treatments for their pets.”

Say hello to Choom^TM
Choom is an emerging adult use cannabis company whose mission is to establish one of the largest retail networks in Canada and the United States. The Choom brand is inspired by Hawaii’s “Choom Gang”—a group of buddies in Honolulu during the 1970’s who loved to smoke weed—or as the locals called it, “Choom”. Evoking the spirit of the original Choom Gang, our brand caters to the Canadian adult use market with the ethos of ‘cultivating good times’. Choom is focused on delivering an elevated customer experience through our curated retail environments, offering a diversity of brands for Canadians across a national retail network.

About Better Choice Company, Inc.
At the foundation of Better Choice is the belief that good health practices and nutrition contribute to and promote a higher quality of life. Recently, Better Choice entered into definitive agreements to acquire TruPet an online seller of pet foods, flea and tick products pet nutritional products and related pet supplies and Bona Vida, an innovative emerging CBD platform, focused on developing a portfolio of brand and product verticals within the animal and human health and wellness space. For more information, please visit and https://www.betterchoicecompany.com.

“Chris Bogart”
President & CEO

Cautionary Statement:

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking information          
This news release contains forward-looking information relating to the Company’s proposed activities and other statements that are not historical facts. Forward-looking information relates to management’s future outlook and anticipated events or results, and include statements or information regarding the future plans or prospects of the Company. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. These factors include risks and uncertainties associated with or arising as a result of delays in obtaining or an inability to obtain required regulatory approvals, access to sufficient quantities of cannabis, the results of diligence investigations, the actions of third parties, the results of negotiations with third parties, developments in the cannabis sector, the ability to access sufficient capital from internal and external sources, reliance on key personnel, regulatory risks and delays and other risks and uncertainties discussed in the management discussion and analysis section of the Company’s interim and most recent annual financial statement or other reports and filings, including those made with the CSE and applicable Canadian securities regulators. There can be no assurance that such forward looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information.

SOURCE Choom Holdings Inc.

For further information: Choom Holdings Inc.: Chris Bogart, President & CEO, T: 604.683.2509, F: 604.683.2506, E: chris@choom.ca; Alex Porporo, Investor Relations, T: 604.683.2509 Ext. 231, F: 604.683.2506, E: alex@choom.ca

Related Links

www.standardgraphite.com

CALGARY, March 28, 2019 /CNW/ – High Tide Inc. (“High Tide” or the “Company”) (CSE:HITI) (Frankfurt:2LY), an Alberta-based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced that it has been licensed to open its 11th Canna Cabana retail store, which is located at 100 Stockton Avenue in Okotoks, Alberta (the “Okotoks Store”). Having met all municipal business requirements, the Okotoks Store is approved to sell smoking accessories and cannabis lifestyle products while the temporary suspension of incremental cannabis retail licensing (the “Moratorium”) by Alberta Gaming, Liquor and Cannabis (the “AGLC”) remains in effect.

Fittingly, the town of Okotoks is Alberta’s 11^th-most populous place with approximately 30,000 current residents. “The opening of the Okotoks Store marks yet another milestone in our goal of establishing Canna Cabana as the retailer of choice for cannabis consumers in Canada,”  said Raj Grover, President and Chief Executive Officer of High Tide. “Okotoks is a young, vibrant and growing community, and I can’t think of a better fit for the Canna Cabana experience,” added Mr. Grover. Store employees will now be able to have conversations with those in the community who are curious about cannabis, assist customers with their smoking accessory needs and introduce them to the sophisticated, approachable and playful Canna Cabana brand.

The Company currently has 36 of the 37 effective maximum number of development permits established by the AGLC for retail cannabis stores across Alberta and expects to receive the one remaining development permit in the near future. High Tide continues to advance its next 25 Canna Cabana locations, which are under various stages of development and construction. The Company is also progressing through the necessary steps to complete two pending retail acquisitions in Saskatchewan and assisting with the opening and operation of three cannabis retail locations in Ontario located in the cities of Sudbury, Hamilton and Toronto.

Additionally, the Company has entered into a debt settlement agreement with an arm’s-length service provider, pursuant to which High Tide intends to settle an amount of up to $400,000 owed through the issuance of up to 800,000 common shares of the Company at a deemed price of $0.50 per common share. High Tide anticipates that the settlement will close on or about April 2, 2019. Lastly, on March 24, 2019, the Company accepted the resignation of Mr. Paul Rosen from its Board of Directors. High Tide would like to thank Mr. Rosen for his guidance to date and looks forward to his ongoing support as a shareholder. The Company wishes Mr. Rosen well in his future endeavours.

About High Tide Inc.

High Tide is an Alberta-based, downstream cannabis corporation focused on the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products. It is a vertically-integrated company in the Canadian cannabis market, with portfolio subsidiaries including RGR Canada Inc., Famous Brandz Inc., Kush West Distribution Inc., Smoker’s Corner Ltd., Grasscity.com, Canna Cabana Inc. and the majority of KushBar Inc. High Tide’s strategy as a parent company is to extend and strengthen its integrated value chain, while providing a complete customer experience and maximizing shareholder value. Key industry investors in High Tide include Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) and FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9).

Representing the core of High Tide’s business, RGR Canada Inc. is a high-quality and innovative designer, manufacturer and distributor of cannabis accessories. Famous Brandz Inc. is a dominant manufacturer of licensed lifestyle accessories, through partnerships with celebrities and entertainment companies including Snoop Dogg and Paramount Pictures. Famous Brandz products are sold to wholesalers and retailers around the world. Founded in 2009 and approved by the Canadian Franchise Association, Smoker’s Corner Ltd. is among Canada’s largest counter-culture chains with 12 locations. Kush West Distribution is in the process of becoming a cannabis wholesaler in the province of Saskatchewan. Based in Amsterdam since 2000, Grasscity.com is the world’s preeminent and most searchable online retailer of smoking accessories and cannabis lifestyle products with approximately 5.8 million site visits annually. With the deregulation of recreational cannabis for adult use across Canada, Canna Cabana Inc., with 11 current locations, is in the process of becoming a sizeable retail brand with a sophisticated yet playful customer experience, while KushBar Inc. is a retail concept that will also be focused on the valued Canadian cannabis consumer.

For more information about High Tide Inc., please visit www.hightideinc.com and its profile page on SEDAR at www.sedar.com.

Forward-Looking Information

Certain statements in this news release are forward-looking information or forward-looking statements. Such information and statements, referred to herein as “forward-looking statements” are made as of the date of this news release or as of the date of the effective date of information described in this news release, as applicable. Forward-looking statements relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (generally, forward-looking statements can be identified by use of words such as “outlook”, “expects”, “intend”, “forecasts”, “anticipates”, “plans”, “projects”, “estimates”, “envisages, “assumes”, “needs”, “strategy”, “goals”, “objectives”, or variations thereof, or stating that certain actions, events or results “may”, “can”, “could”, “would”, “might”, or “will” be taken, occur or be achieved, or the negative of any of these terms or similar expressions, and other similar terminology) are not statements of historical fact and may be forward-looking statements.

Such forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to the ability of High Tide to execute on its business plan and that High Tide will receive one or multiple licenses from Alberta Gaming, Liquor & Cannabis, British Columbia’s Liquor Distribution Branch or the Saskatchewan Liquor and Gaming Authority permitting it to carry on its Canna Cabana Inc. and KushBar Inc. businesses. High Tide considers these assumptions to be reasonable in the circumstances. However, there can be no assurance that any one or more of the government, industry, market, operational or financial targets as set out herein will be achieved. Inherent in the forward-looking statements are known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements, or industry results, to differ materially from any results, performance or achievements expressed or implied by such forward-looking statements.

The forward‐looking statements contained herein are current as of the date of this news release. Except as required by law, High Tide does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances. Any and all forward-looking statements included in this news release are expressly qualified by this cautionary statement, and except as otherwise indicated, are made as of the date of this news release.

SOURCE High Tide Inc.

For further information: please contact Nick Kuzyk, Chief Strategy Officer & SVP Capital Markets at High Tide Inc.; Tel: (403) 265-4207; Email: Nick@HighTideInc.com; Web: www.HighTideInc.com

VANCOUVER, March 28, 2019 /CNW/ – Nextleaf Solutions Ltd. (“Nextleaf” or the “Company“) (CSE: OILS) is pleased to announce that it has been issued a patent by the United States Patent and Trade Office pertaining to the Company’s proprietary process of extraction, refinement, and distillation of cannabinoids from marijuana and hemp.

The resulting THC or CBD distillate is tasteless, odourless, standardized for potency, and ready to use in a wide range of products, including topicals, transdermal or sublingual delivery technology, vape technology, edible oils, beverages, and water-soluble extracts. Nextleaf’s patented technology allows for low-quality dried cannabis biomass to be efficiently processed into a high-purity distilled oil, simplifying the manufacturing of differentiated cannabinoid formulations and delivery methods.

Nextleaf is pleased to further announce that it has been issued a standard patent by IP Australia – the Australian Government agency that administers intellectual property (“IP”) rights – for the Company’s unique, industrial-scale process of producing purified cannabinoid distillate.

The Company’s management believes, to the best of its knowledge, that Nextleaf is the first publicly traded company to be issued a patent for the extraction and purification of cannabinoids.

“Nextleaf Solutions has succeeded in beating big pharma, big tobacco, big alcohol, and every single billion-dollar cannabis company to the first issued patent for the extraction and purification of cannabinoids.” said Paul Pedersen, CEO. “We believe companies that can develop and protect valuable intellectual property will benefit substantially in the long-term, especially in an industry as young as the cannabis industry.

Currently, legal cannabis producers in Canada can only sell one form of cannabis extract (“cannabis oil”) with a maximum potency of approximately 3% THC. However, the Federal Government has announced that cannabis concentrates, edibles, beverages, topicals, and vape pens will be legal by October 2019, and is expected to publish draft regulations in the coming months. These products are extremely popular in other legal cannabis jurisdictions, and demand for them continues to grow.

“Nextleaf’s patented process allows a cannabis processor to turn raw biomass or a crude extract into a refined, high-purity oil that’s tasteless, odourless, easy to standardize, or even make water soluble. Developed by Nextleaf’s team of chemists and engineers, it allows us to efficiently separate and isolate THC and CBD molecules at an industrial scale, before reformulating in the ideal combination based on the product, client, and end consumer’s needs. The mass-market consumer is looking for a consistent experience to either reliably target a particular medical condition, or to bring about a desired effect. We expect Nextleaf’s issued patent will have a major impact on the production of the next generation of legal cannabis products, especially since most federally-legal cannabis processors seem to be lacking the technology and expertise to do it themselves,” said Nextleaf Co-Founder and CEO Paul Pedersen.

Nextleaf’s patented process improves upon traditional extraction methods that use only CO₂ or ethanol to produce crude cannabis extracts. Unrefined botanical extracts contain chlorophyll, fats, and other impurities that result in undesirable flavours and aromas when consumed. Nextleaf’s unique method of extracting and separating cannabinoids and terpenes makes it possible to purify and concentrate the desired compounds, which can be used for the manufacturing of a diverse array of products standardized for dose.

The Company initially files its patents in the United States to create a priority date and allow for future filings in other selected jurisdictions. This is common in the field of IP protection. Following the issuance of its patent in the United States, Nextleaf filed for patent protection in Canada, Europe, Mexico, Colombia, and Jamaica. These patent filings are part of the Company’s overall strategy to develop and protect IP pertaining to the production of innovative cannabinoid-based products geared towards both medical cannabis patients and adult-use consumers.

About Nextleaf Solutions

Nextleaf Solutions Ltd. (CSE: OILS) is an extraction technology company that has developed a portfolio of issued and pending patents pertaining to the company’s unique, industrial-scale process of producing purified cannabinoid distillate, a tasteless, odourless cannabis concentrate best suited for infusing premium value-added products. Nextleaf plans to commercialize its intellectual property portfolio by providing B2B processing services to licensed cultivators and supplying cannabis oil and extracts to qualified Canadian and international partners under the client’s own brands. Nextleaf has completed construction of its dedicated extraction and processing facility in Greater Vancouver, British Columbia, in time for Canada’s legalization of edibles and other cannabis derivative products. The Company’s processing facility includes research and laboratory infrastructure, allowing for the continued development of novel, scalable cannabis processing technology and intellectual property.

For more information about Nextleaf Solutions (CSE: OILS) visit  www.nextleafsolutions.com or follow Nextleaf across social media platforms.

Contacts

Adel Fares, Investor Relations
604-283-2301 (ext. 201)
investors@nextleafsolutions.com

Paul Pedersen, CEO
604-347-9160
paul@nextleafsolutions.com

CAUTIONARY STATEMENT:
The securities described herein, if any, have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any of Nextleaf Solutions securities in the United States. This news release may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of Nextleaf Solutions, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of Nextleaf Solutions and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of Nextleaf Solutions future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from Nextleaf Solutions’ expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to Nextleaf Solutions, reference should be made to Nextleaf Solutions continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Nextleaf Solutions CSE Listing Statement. The forward-looking information contained in this release is made as of the date of this release. Nextleaf Solutions does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents of this press release. To contact the company, email investors@nextleafsolutions.com

SOURCE Nextleaf Solutions Ltd.

Related Links

https://www.nextleafsolutions.com

TORONTO, March 28, 2019 /CNW/ – Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF)www.libertyhealthsciences.com (“Liberty” or the “Company”), a provider of high quality cannabis, announced today that it has entered into an in-licensed agreement with The Werc Shop for its patented and patent-pending terpene technology. The Werc Shop is a world-renowned scientific consulting group recognized as the leaders in cannabis terpene analysis and terpene-based formulations, and its cutting-edge technology will enable Liberty to provide superior, standardized, and consistent medical cannabis products to the Florida market.

“We are excited to be working with such a powerful technology,” said Victor E. Mancebo, interim Chief Executive Officer of Liberty. “Dr. Jeffrey Raber and his team have an incredible depth of understanding of the science of cannabis, which is reflected in the professional products they deliver to the market. Cannabis compositions created by The Werc Shop have long been market leaders on the West Coast, and we’re excited to bring this technology and know-how to Florida. With access to this team and their intellectual property, Liberty will rapidly advance on our efforts to deliver the best cannabis products to the patients of Florida.”

Liberty focuses on providing the patient with a tailored experience that ultimately delivers the right medicine to meet their ailment’s needs. Accessing technology that enables the creation of customized cannabis compositions will improve upon Liberty’s goal of delivering the right cannabis medicine to each and every patient.

“We’re very excited to bring our cannabis formulation expertise to Florida with Liberty Health Sciences,” said Jeffrey C. Raber, Ph.D., founder and Chief Executive Officer of The Werc Shop. “This relationship will further our goals of delivering superior cannabis formulations to adults across the wellness spectrum. We look forward to developing specialized cannabis compositions for the Florida market through our relationship with Liberty.”

“At Liberty, we pride ourselves in providing our patients with the highest quality medicinal cannabis products in the market,” said Mancebo. “Partnering with The Werc Shop solidifies our commitment to provide top grade cannabis derived products for our patients.”

The Werc Shop has been developing proprietary scientific solutions for medical cannabis markets since 2010 and currently holds eight issued patents in connection with their technologies. The Werc Shop delivers sophisticated and standardized complex cannabis products in a safe and effective manner through its suite of proprietary technologies and know-how.

About The Werc Shop
Founded in 2010, The Werc Shop® was the first company to analyze the fingerprints of over a thousand unique cannabis strains, building a scientific knowledge-base that spurred the global terpene market. This scientific foundation is the basis for all of our terpene and flavor blends. The Werc Shop formulations contain over 60 different components and represent the most TRUE TO PLANT formulations on the market today.

Today, The Werc Shop is dedicated to helping licensed cannabis businesses innovate and produce the highest-quality products that meet the diverse needs of the cannabis consumer through use of our proprietary intellectual property via our consulting and formulation services. The Werc Shop scientists have more than 100 years of combined experience studying cannabis and developing world-class products, supported by a broad foundation of issued and pending patents world-wide.

About Liberty Health Sciences Inc.
Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale. Liberty’s measured approach to expansion opportunities is focused on maximizing returns to shareholders, while keeping consumers’ well-being at the forefront of what we do. For more information, please visit: www.libertyhealthsciences.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “believe”, “plan”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company’s production capabilities, expectations concerning the receipt of all necessary approvals from the Florida Department of Health, expectations concerning the opening of new dispensaries and the expansion of its greenhouse space, and the Company’s future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE Liberty Health Sciences Inc.

For further information: Media Contacts: Dwain Schenck, (203) 223-5230, dwain@schenckstrategies.com; Victor Mancebo, Interim Chief Executive Officer, (386) 462-0141, VMancebo@libertyhealthsciences.com

COSTA MESA. Calif., March 26, 2019 /CNW/ — Orchid Ventures, Inc. (“Orchid”), with its award-winning cannabis brand Orchid Essentials, initiated trading on the CSE under the ticker ORCD on March 18, 2019. This is yet another milestone for the fast-growing Cannabis brand that became a top-selling brand the first year it entered the Oregon market and has plans to meet those same goals in California this year.  Orchid was co-founded by Corey Mangold, a serial entrepreneur that has founded multiple successful ventures, and built and marketed brands of products sold around the world, and Rene Suarez, an entrepreneur with a proven track record of developing products that the consumer is looking for in the market. Both Corey and Rene are California natives.

“The public listing of our shares signifies an important milestone for our company as we seek to expand our footprint in our current markets of California, Oregon and beyond,” says Corey Mangold CEO and Co-Founder of Orchid Essentials. “We are also gratified to offer our loyal customers and the public access to our shares alongside our longtime early investors.”

“Since day one, Corey and I set out to build a company focused on premium quality, calculated expansion and a strong brand,” says Rene Suarez, President and Co-Founder of Orchid Essentials. “Finding the right partners has been critical in our growth in this emerging market. Our listing on the CSE is a big step towards reaching our goal, and, establishing Orchid as a leading cannabis company across global markets. Keep watching as there is so much more coming from our team in the near future.”

As the CEO of Orchid, Corey brings 20 years of start-up experience and a knack for developing successful companies. Corey is also the principal and co-founder of Gigasavvy, a leading southern California creative marketing agency. He’s established a thriving agency that has launched and managed campaigns for Toshiba, Knott’s Berry Farm, Johnny Rockets, Hi-Chew Candy, Tenet Healthcare and Northgate Markets to name a few. Corey has also worked tirelessly to create a thriving culture at Gigasavvy that has been recognized, 4 out of the last 5 years, as a “Top 10 Places” to work in Orange County.

As the President of Orchid and former CSO/Partner at Space Jam, a leader in the nicotine/vape juice industry, Rene Suarez brings years of experience in supply chain operations and sales management and has a keen eye for accounting and statistics. At the beginning of his tenure with Space Jam, the company was generating $80k/mo. Through Rene’s vision and strategic execution, sales grew rapidly over $1.6MM/mo in less than 6 months. Rene was ultimately responsible for driving over $15MM in sales revenue in 2014 which catapulted Space Jam towards becoming an industry leader.

As validation for the brand and the management team, Orchid was able to attract Tom Soto and Robert MacDonald,  sophisticated and experienced political and financial influencers, to its Board of Directors.

Tom Soto is the Chairman of the Board for Orchid, and a long-time investor in the impact sector. His leadership, voice and investments range from Fintech, to electric vehicle technology and policy, to political process, regulatory frameworks and more. His presence in the impact sector as an investor and opinion leader over the past twenty years has been substantial, creating tectonic shifts in policy and in the lives of millions of people who now benefit from improved health policies. Mr. Soto was also an appointee of President Bill Clinton to the State Department’s Border Environmental Cooperation Commission which oversaw the $2.5b North American Development Bank’s activities. In addition, he was President Barack Obama’s Co-lead of the Executive Office of the President’s Transition Team for The White House Council on Environmental Quality from November of ’08 to January of ’09.

Robert MacDonald is the Chair of the Audit Committee for Orchid and, an influential, trusted advisor with deep Board and corporate governance expertise in energy, clean technology, banking, and manufacturing industries. He has had success in raising billions of dollars in capital to catapult startups and growth companies into thriving, profitable entities. Mr. MacDonald has served on 23 Board of Directors for 16 private and 7 public companies and has raised over $8 billion in funds over his extensive career. His experience varies from co-founding and leading the development of one of the country’s first fully integrated independent power production companies to helping create two of the largest municipal joint action agencies in California.

Within two years of formation, Orchid has secured distribution in over 250 locations and offers 12 SKUS with many more in development. Orchid has plans to expand into new markets in the US and globally. Orchid is in the process of securing licensing to gain more control of its supply chain and plans to launch its first phase of its CBD line next month.

About CSE
The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets.

About Orchid Essentials
Orchid is an award-winning cannabis brand with THC and CBD product lines currently sold in 250+ dispensaries across California and Oregon. Orchid plans to expand its brand into new markets such as Nevada, New York, Puerto Rico, Canada and other global markets. With a continued focus on brand and intellectual property development, Orchid will execute strategic acquisitions to solidify an integrated cannabis manufacturing and distribution infrastructure with the goal of becoming a dominant premium cannabis brand in the United States. Orchid’s management brings significant branding, product development, manufacturing, and distribution experience with a proven track record of scaling revenues, building value generating partnerships, and creating enterprise value.

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN.

Contact: Rosie Mattio, rosie@rosiemattiopr.com